New malaria shots could replace daily pills

NCT ID NCT07011511

Recruiting now Prevention Sponsor: Medicines for Malaria Venture Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests whether two new long-acting injectable drugs, MMV055 and MMV371, are safe and how they work in the body. Up to 72 healthy adults will receive one or two shots and be monitored for up to 48 weeks. The goal is to find a dose that could one day prevent malaria with just a few injections.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MMV055 and MMV371 (long-acting injectable drugs)
What this could lead to: If successful, this could lead to a long-acting injection that prevents malaria for weeks or months, reducing the need for daily pills.
What could go wrong: This is a very early (Phase 1) safety study in only 72 healthy people. The drugs may not work as hoped or could cause side effects like injection site reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALARIA,FALCIPARUM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malaria prevention target Plasmodium falciparum malaria prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALARIA,FALCIPARUM

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Quotient Sciences
RECRUITING

Nottingham, NG11 6JS, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.